Home

Person

Bernard Schneider

About
Privacy
Disclaimer

Graph Chatbot

Related publications (114)

Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease

Parkinson disease (PD) is characterized by the progressive degeneration of substantia nigra dopaminergic neurons projecting to the striatum. Since the deficit in striatal dopamine is the main cause of PD symptoms, it appears critical to preserve axon termi ...

2004

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease

Manuel Bauer, Patrick Aebischer, Christophe Lo Bianco, Bernard Schneider

Parkinson's disease (PD) is characterized by a progressive loss of midbrain dopamine neurons and the presence of cytoplasmic inclusions called Lewy bodies. Mutations in several genes including alpha-synuclein and parkin have been linked to familial PD. The ...

National Academy of Sciences2004

Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery

Patrick Aebischer, Bernard Schneider

The present study investigates the respective roles of both the host immune response and the metabolic requirements in determining the long-term survival of erythropoietin-secreting myoblasts within encapsulating polymer membranes. Hollow-fiber capsules lo ...

2003

Cellular implants: pioneers in xenotransplantation?

Patrick Aebischer, Bernard Schneider

2003

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease

Patrick Aebischer, Nicole Déglon, Christophe Lo Bianco, Bernard Schneider

Parkinson's disease (PD) is characterized by the progressive loss of substantia nigra dopaminergic neurons and the presence of cytoplasmic inclusions named Lewy bodies. Two missense mutations of the alpha-synuclein (alpha-syn; A30P and A53T) have been desc ...

National Academy of Sciences2002

Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia

Patrick Aebischer, Nicole Déglon, Bernard Schneider

BACKGROUND: Existing animal models of anemia inadequately reflect the hematocrit usually present in chronic renal failure (CRF) patients and do not permit long-term treatment studies. The transgenic mouse strain 134.3LC (Epo-TAg(H)) displays a severe chron ...

2002

Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts

Patrick Aebischer, Nicole Déglon, Bernard Schneider

We developed an ex vivo gene therapy approach for the regulated delivery of therapeutic proteins based on the implantation of encapsulated, genetically engineered C(2)C(12) myoblasts. We investigated doxycycline-based regulation of gene expression to modul ...

2002

A self-immunomodulating myoblast cell line for erythropoietin delivery

Patrick Aebischer, Bernard Schneider

The transplantation of genetically engineered cells faces limitations associated with host immunity. Allogeneic cells are typically rejected in response to inherent histo-incompatibility. Even autologous cells can induce an immune response toward antigenic ...

2001

Inducing host acceptance to encapsulated xenogeneic myoblasts

Patrick Aebischer, Bernard Schneider

BACKGROUND: Cell encapsulation holds promise for the chronic delivery of recombinant proteins such as erythropoietin. Encapsulated xenogeneic mouse C2C12 myoblasts display long-term survival in the central nervous system whereas they do not in the subcutan ...

2001

Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2

Patrick Aebischer, Bernard Schneider

Neural stem cells (NSCs), when stimulated with epidermal growth factor (EGF) or fibroblast growth factor-2 (FGF-2), have the capacity to renew, expand, and produce precursors for neurons, astrocytes, and oligodendrocytes. We postulated that the early appea ...

2001

Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression

Patrick Aebischer, Bernard Schneider

BACKGROUND: Encapsulating cells prevents the immune destruction of allogeneic cells in the subcutaneous site as well as allogeneic and xenogeneic cells in the central nervous system. However, when encapsulated xenogeneic cells are implanted s.c., they may ...

2000

Highlights of the cell transplantation meeting at Montreux, March 1999

Patrick Aebischer, Bernard Schneider

1999

Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts

Patrick Aebischer, Nicole Déglon, Bernard Schneider

The transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated ...

1998

Absorption dans l'eau de SO2 à faibles concentrations, sur des remplissages constitués de tôles ondulées

Bernard Schneider

EPFL1975

Page 6 of 6